Tumor Necrosis Factor Blocker [EPC]

794986 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	92733
1	INJECTION SITE PAIN	57525
2	ARTHRALGIA	51742
3	PAIN	46968
4	RHEUMATOID ARTHRITIS	46333
5	OFF LABEL USE	43168
6	INJECTION SITE ERYTHEMA	41450
7	FATIGUE	34997
8	HEADACHE	28589
9	PSORIASIS	27943

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	285	0.9760
1	INJECTION SITE RECALL REACTION	481	0.9737
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	2950	0.9404
3	SWOLLEN JOINT COUNT INCREASED	578	0.9017
4	RHEUMATOID FACTOR POSITIVE	2548	0.8786
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1605	0.8386
6	PEMPHIGUS	5335	0.7967
7	RHEUMATIC FEVER	751	0.7914
8	C-REACTIVE PROTEIN ABNORMAL	2601	0.7762
9	HAND DEFORMITY	5485	0.7202

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]